使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning and welcome to the Insulet Corporation fourth quarter and full year 2025 earnings call. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Clare Trachtman, Vice President, Investor Relations.
早安,歡迎參加 Insulet Corporation 2025 年第四季暨全年財報電話會議。提醒各位,本次電話會議將被錄音。現在我想把會議交給今天的主持人——投資人關係副總裁 Clare Trachtman。
Clare Trachtman - Vice President, Investor Relations
Clare Trachtman - Vice President, Investor Relations
Good morning and welcome to our fourth quarter in full year 2025 earnings call. Joining me today are Ashley Mcevoy, President and Chief Executive Officer, Flavia Pease, Chief Financial Officer, and Eric Benjamin, Chief Operating Officer.
早安,歡迎參加我們 2025 年第四季暨全年財報電話會議。今天與我一同出席的有總裁兼執行長 Ashley Mcevoy、財務長 Flavia Pease,以及營運長 Eric Benjamin。
On the call this morning, we will be discussing Insulet's fourth quarter and full year results along with our financial outlooks for the first quarter and full year 2026. With that, let me start our prepared remarks by reminding everyone that certain statements, including comments regarding our financial outlook for the first quarter in full year 2026.
今天早上的電話會議中,我們將討論 Insulet 的第四季與全年業績,以及我們對 2026 年第一季與全年之財務展望。在此,我先以預先準備的發言提醒各位,某些陳述(包括我們對 2026 年第一季與全年財務展望的評論)
The anticipated impact of our strategic actions, the potential impact of various regulatory and operational matters, and the macroeconomic environment on the results of operations contain forward-looking statements that involve risks and uncertainties.
以及我們策略行動的預期影響、各項法規與營運事項的潛在影響,與總體經濟環境對營運結果的影響,均屬於涉及風險與不確定性的前瞻性陳述。
And of course, our actual results could differ materially from our current expectations. Please refer to today's press release in our SEC filing for more detail concerning factors that could cause actual results to differ materially.
當然,我們的實際結果可能與目前預期有重大差異。請參閱今日新聞稿與我們向 SEC 提交的文件,以取得可能導致實際結果與預期有重大差異之因素的更多細節。
In addition, on today's call, non-GAAP financial measures will be used to help investors understand input's ongoing business performance, including adjusted operating income, adjusted EPS, adjusted EBITDA, adjusted tax rates, and constant currency revenue, which is revenue growth excluding the effect of foreign exchange, a reconciliation of certain non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation and available in our earnings release issued this morning, which are both available on our website.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解 Insulet 持續性的營運表現,包括調整後營業利益、調整後每股盈餘(adjusted EPS)、調整後 EBITDA、調整後稅率,以及固定匯率營收(即排除外匯影響的營收成長)。我們今日討論之部分非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已收錄於隨附的投資人簡報中,並可於我們今早發布的財報新聞稿中取得;兩者皆可在我們的網站上查閱。
Additionally, unless otherwise stated, all financial commentary regarding dollar and percentage changes will be on a year-over-year reported basis with the exception of revenue growth rates, which will be on a year-over-year constant currency basis. During the Q&A session this morning, Ashley, Flavia, Eric, and myself will be available to address any questions.
另外,除非另有說明,所有關於金額與百分比變動的財務評論,均以年對年之「報告基礎」呈現;惟營收成長率除外,將以年對年之「固定匯率」基礎呈現。在今天早上的問答環節中,Ashley、Flavia、Eric 與我將回答各位的問題。
Now I'd like to turn the call over to Ashley. Ashley?
現在我想把電話會議交給 Ashley。Ashley?
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Thank you and good morning, everyone. I'm pleased to share that we closed 2025 with another strong quarter, recording our 10th consecutive year of 20% or greater constant currency revenue growth. This consistent track record reflects the strength of our durable recurring revenue, profitable business model, and the breadth and depth of our competitive modes.
謝謝,大家早安。我很高興分享,我們以另一個強勁季度為 2025 年畫下句點,並連續第 10 年達成固定匯率營收成長 20% 或以上。這項一貫的紀錄反映出我們穩健的經常性收入、具獲利能力的商業模式,以及我們競爭護城河的廣度與深度。
Our strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence, and the consistency of our execution, along with the deep commitment of the insolent team to finding a better way for people living with diabetes, has enabled us to deliver enhanced value to all of our stakeholders.
我們強而有力的臨床證據與真實世界成效,持續贏得處方醫師與病患的信心;而我們執行的一致性,加上 Insulet 團隊致力於為糖尿病患者找到更好方式的深厚承諾,使我們得以為所有利害關係人創造更高的價值。
I want to start by thanking our Insulet employees around the world. 2025 was a year of significant progress at Insulet, and the entire organization delivered on our goals without missing a beat. Your dedication to our mission fills me with confidence today and well into our future.
我想先感謝全球的 Insulet 員工。2025 年對 Insulet 而言是進展顯著的一年,而整個組織在達成目標的過程中毫不失誤。你們對使命的投入,讓我對當下以及未來充滿信心。
Our results in the fourth quarter are a testament to the reliability, consistency, and broad appeal of Omnipod coupled with the strength of our strategy and execution. Total company revenues were $784 million advancing 29% constant currency. US revenues of $568 million increased 28% and international revenues of $214 million grew 42% constant currency.
我們第四季的成果證明了 Omnipod 的可靠性、一致性與廣泛吸引力,並展現我們策略與執行力的強勁。公司總營收為 7.84 億美元,固定匯率成長 29%。美國營收 5.68 億美元,成長 28%;國際營收 2.14 億美元,固定匯率成長 42%。
This strong finish to the year enabled us to surpass $2.7 billion in revenue for the full year, more than doubling our revenue base over the last three years and delivering approximately 30% year-over-year constant currency growth.
這樣強勁的年末表現,使我們全年營收突破 27 億美元;在過去三年中,我們的營收基礎增加逾一倍,並實現約 30% 的年對年固定匯率成長。
Our annual performance of $1.9 billion or 27% growth in the US, and $754 million or 39% constant currency growth in international markets highlights the progress and the impact we're making, as we continue to unlock more of our $30 billion-plus total addressable market.
我們全年在美國達成 19 億美元、成長 27%;在國際市場達成 7.54 億美元、固定匯率成長 39%。這凸顯了我們持續解鎖超過 300 億美元總可服務市場(TAM)所取得的進展與影響力。
We achieved record new customer starts across both the US and international in the fourth quarter and for the full year, with the vast majority coming from people transitioning from multiple daily injections. This reflects growing provider confidence, which, as I just mentioned, is driven by strong clinical evidence and consistent real-world outcomes.
我們在第四季與全年於美國與國際市場皆創下新客啟用(new customer starts)紀錄,其中絕大多數來自由每日多次注射(MDI)轉換而來的使用者。這反映出醫療提供者信心的提升;如我剛才提到,這是由強勁的臨床證據與一致的真實世界成效所驅動。
Importantly, it also reinforces that Insulet is not only the market leader in AID, but also the clear driver of overall market expansion, and we intend to maintain this leadership position. Turning to our key markets and starting with our largest, US type 1, where we continue to focus on extending our leadership.
更重要的是,這也再次印證 Insulet 不僅是自動胰島素輸注(AID)市場的領導者,更是整體市場擴張的明確推動者,而我們也打算維持這一領導地位。接下來談我們的主要市場,先從最大市場——美國第一型糖尿病——開始,我們持續聚焦於延伸我們的領導優勢。
The US type 1 market is a more than $9 billion opportunity with AID penetration at just 40%, which is well behind CGM penetration of 70%. In 2025, we delivered year-over-year growth in type 1 new customer starts in both the fourth quarter and the full year, driven by strong patient and prescriber preference for Omnipod. In fact, both type 1 and type 2 users in the US named Omnipod 5 their favorite pump in 2025.
美國第一型糖尿病市場是一個超過 90 億美元的機會,而 AID 滲透率僅 40%,明顯落後於 CGM 70% 的滲透率。2025 年,我們在第四季與全年皆實現第一型糖尿病新客啟用的年對年成長,主要由病患與處方醫師對 Omnipod 的強烈偏好所帶動。事實上,2025 年美國第一型與第二型使用者都將 Omnipod 5 評為最喜愛的幫浦。
Omnipod's strong clinical evidence, broad access, affordability, and ease of use are enabling us to expand well beyond traditional endocrinology channels. Our US prescriber base now includes more than 30,000 healthcare professionals, up approximately 28% year-over-year.
Omnipod 強勁的臨床證據、廣泛的可及性、可負擔性與易用性,使我們得以大幅拓展至傳統內分泌科以外的通路。我們在美國的處方醫師基礎目前已包含超過 30,000 名醫療專業人員,年對年約成長 28%。
The strength and reach of our commercial teams positioned this segment to remain a meaningful and consistent contributor to our global customer growth. Momentum in the US type 2 continues to build as well. In the fourth quarter, type 2 new customer starts grew significantly, both sequentially and year-over-year, rapidly expanding our type 2 user base.
我們商業團隊的實力與覆蓋範圍,使該業務區隔得以持續成為全球客戶成長的重要且穩定的貢獻來源。美國第二型糖尿病市場的動能也持續增強。第四季第二型糖尿病新客啟用無論較前一季或年對年皆顯著成長,快速擴大我們的第二型使用者基礎。
This acceleration reflects strong clinical and real-world outcomes, continued investment and demand generation, and the recent ADA guideline update recommending AID for people with type 2, who require insulin. Our type 2 prescriber base grew 62% in 2025 to now more than 6,500 clinicians. Most people with type 2 diabetes are being managed in primary care settings. Therefore, expanding beyond endocrinology represents a meaningful and sustainable growth opportunity.
這樣的加速反映了強勁的臨床與真實世界成效、持續的投資與需求創造,以及近期 ADA 指引更新,建議對需要胰島素的第二型糖尿病患者使用 AID。我們的第二型處方醫師基礎在 2025 年成長 62%,目前已超過 6,500 名臨床人員。多數第二型糖尿病患者是在基層醫療(primary care)場域接受管理。因此,拓展至內分泌科以外,代表一個重要且可持續的成長機會。
In a type 2 market of more than $12 billion where AID penetration remains below 5%, which is far behind roughly 55% of CGM adoption, stronger education, improved outcomes, and increasing access are already accelerating adoption.
在一個超過 120 億美元、AID 滲透率仍低於 5% 的第二型市場中,這遠落後於約 55% 的 CGM 採用率;更強的教育、更佳的結果與更高的可及性,已在加速採用。
Importantly, we are unlocking this opportunity in a strategic and capital efficient way. Our US sales force, which is the largest in the industry, reaches high prescribing offices that treat both type 1 and type 2 diabetes, giving us confidence in our ability to unlock the next 5% to 10% of type 2 penetration efficiently.
重要的是,我們正以具策略性且資本效率高的方式解鎖這項機會。我們的美國銷售團隊是業界最大,能觸及同時治療第一型與第二型糖尿病、且處方量高的診所,讓我們有信心能有效率地解鎖第二型滲透率接下來 5% 到 10% 的提升空間。
Our growing type 2 customer base continues to surface powerful stories about the impact Omnipod 5 can have, including the experience of Verquise. He knew something was wrong when he began experiencing pain in its feet and arms and an urgent care visit led them to an unexpected diagnosis of type 2 diabetes.
我們持續成長的第二型客戶基礎,也不斷浮現 Omnipod 5 能帶來影響力的有力故事,其中包括 Verquise 的經歷。當他開始感到腳與手臂疼痛時,他知道情況不對;一次緊急照護(urgent care)就診,讓他意外被診斷為第二型糖尿病。
After reviewing insulin delivery options with his doctor, [Verquise] chose Omnipod because he shared, I really love the mission and the promise that was exuberated from Omnipod to add normalcy to my diabetes and to show that my life can still be balanced.
在與醫師一起檢視胰島素輸注選項後,[Verquise] 選擇了 Omnipod;他分享道:「我真的很喜歡 Omnipod 的使命,以及 Omnipod 所傳達的承諾——為我的糖尿病生活增添正常感,並讓我知道我的人生仍然可以保持平衡。」
And that this brand, this family will always be there and will forever evolve as medical technology does. Stories like Verquise, combined with the growing excitement among both healthcare professionals and people with type 2 diabetes, continue to strengthen our conviction in a significant type 2 market opportunity.
「而且這個品牌、這個大家庭將永遠在那裡,並會隨著醫療科技的發展而不斷進化。」像 Verquise 這樣的故事,加上醫療專業人員與第二型糖尿病患者之間日益高漲的熱情,持續強化我們對第二型市場重大機會的信念。
Looking ahead, we expect to expand penetration even further with the launch of our fully closed-loop offering planned in 2028, which will enable us to reach and serve the broader primary care population. Additionally, pharmacy access remains a critical differentiator in the US, making it easier for people with diabetes to start and stay on therapy.
展望未來,我們預期將在2028年推出計畫中的全閉環解決方案,進一步提升滲透率,使我們能觸及並服務更廣泛的基層醫療族群。此外,在美國,藥局通路可近性仍是關鍵差異化優勢,讓糖尿病患者更容易開始治療並持續遵從療程。
Over the past decade, we've built strong relationships with payers and PDMs across the US, backed by clinical and economic evidence that continues to resonate. We have the broadest access in the market available in approximately 48,000 US pharmacies and covered for more than 90% of insured lives or about 300 million of the 370 million insured people.
過去十年,我們在全美與保險支付方及PDM建立了穩固的合作關係,並以持續具說服力的臨床與經濟證據作為支撐。我們擁有市場上最廣泛的可近性,約在美國48,000家藥局可取得,且涵蓋超過90%的投保人口,約為3.7億投保人中的3億人。
Our offering is affordable with most users paying about $1 a day through our pay-as-you-go model and preferred formulary position. And we continue to invest in programs designed to further reduce the remaining barriers to access, including efforts to simplify the prior authorization process for providers, particularly among primary care prescribers who treat large numbers of people with type 2 diabetes.
我們的方案具可負擔性,多數使用者透過按用量付費模式與優先給付名單地位,每天約支付1美元。我們也持續投資於旨在進一步降低剩餘取得障礙的計畫,包括簡化醫療提供者的事前授權流程,特別是針對治療大量第二型糖尿病患者的基層照護開立者。
Omnipod also continued to drive standout international performance. Fueled by strong year-over-year and sequential growth in new customer starts, along with continued positive price/mix realization driven by conversion from Omnipod DASH to Omnipod 5.
Omnipod在國際市場也持續帶動亮眼表現。在新客戶啟用數的年增與季增強勁成長帶動下,加上由Omnipod DASH轉換至Omnipod 5所推動的價格/組合持續正向實現。
We continue to see solid performance across our established European markets, supported by new sensor integrations such as our launch with DexCom G7 in Germany. Our Omnipod 5 launches in Canada and Australia also delivered robust growth. In Canada, we secured reimbursement, recognizing Omnipod 5's value in half of all provinces, helping drive more than 60% growth in new customer starts.
我們在既有的歐洲市場持續看到穩健表現,並受惠於新的感測器整合,例如我們在德國與DexCom G7的上市合作。我們在加拿大與澳洲推出Omnipod 5也帶來強勁成長。在加拿大,我們在全部省份中的一半取得給付,肯定Omnipod 5的價值,進而推動新客戶啟用數成長超過60%。
And in Australia, new customer starts more than tripled following the launch of Omnipod 5. Our global expansion will continue in 2026 with Omnipod 5 and Omnipod Discover recently launching in the Middle East.
而在澳洲,Omnipod 5上市後,新客戶啟用數成長超過三倍。我們的全球擴張將於2026年持續推進,Omnipod 5與Omnipod Discover近期已在中東上市。
In addition, Spain, our newest market, is expected to launch Omnipod 5 later this year. Volume remains the primary driver of our international growth and the ongoing transition from Omnipod DASH to Omnipod 5 will continue to support positive price mix realization. Pricing contributed high single-digit growth in both the fourth quarter and the full year 2025.
此外,西班牙作為我們最新的市場,預計將於今年稍晚推出Omnipod 5。銷量仍是我們國際成長的主要驅動力,而從Omnipod DASH轉換至Omnipod 5的持續進程將繼續支持正向的價格組合實現。定價在第四季與2025全年皆貢獻了高個位數成長。
Our international growth runway remains substantial. The type 1 market alone exceeds $10 billion. Yet only one in four people with diabetes outside the US is using AID therapy, even if CGM penetration reaches around 65%.
我們的國際成長跑道仍然相當可觀。僅第一型糖尿病市場規模就超過100億美元。然而,即使CGM滲透率達到約65%,美國以外的糖尿病患者中仍只有四分之一使用AID治療。
As adoption of AID accelerates worldwide, our proven commercial playbook, expanding product portfolio and growing geographic footprint position us extremely well to continue capturing share, delivering value and driving sustained international growth.
隨著AID在全球加速採用,我們經驗證的商業化作戰手冊、擴大的產品組合與日益成長的地理覆蓋範圍,使我們具備極佳條件持續取得市占、創造價值並推動可持續的國際成長。
To bring this all together, we have a large underpenetrated TAM across US type 1, US type 2 and international markets with significant runway to unlock additional growth in one of the fastest-growing categories in med tech.
綜合而言,我們在美國第一型、美國第二型以及國際市場擁有龐大且滲透率仍低的TAM,具備顯著的成長跑道,可在醫療科技中成長最快的類別之一解鎖更多增長。
And our proven track record reinforced by our performance this year underscores our ability to continue to deliver top-tier growth and value creation for shareholders. Notably, this top-tier growth has allowed us to deliver meaningful margin expansion, even as we continue to invest thoughtfully to extend our competitive advantages in innovation, clinical outcomes, access, brand and manufacturing.
而我們經驗證的績效紀錄,加上今年的表現,更凸顯我們持續為股東帶來頂尖成長與價值創造的能力。值得注意的是,這種頂尖成長使我們即便持續審慎投資以延伸在創新、臨床結果、可近性、品牌與製造方面的競爭優勢,仍能實現具意義的利潤率擴張。
For the year, we achieved record growth and operating margins, delivering 180 basis points of gross margin expansion and 270 basis points of operating margin expansion. We remain committed to investing with discipline, ensuring we sustain the strong growth we are delivering today while also driving continued improvements in profitability.
全年而言,我們達成創紀錄的成長與營業利潤率,毛利率擴張180個基點,營業利潤率擴張270個基點。我們仍致力於以紀律進行投資,確保在維持當前強勁成長的同時,也持續提升獲利能力。
The investments funded by our durable recurring revenue profitable business model and strong financial position, fueled significant progress across every aspect of our strategy in 2025. We expanded our global scale this year with launches in nine new countries, launched our G7 CGM integration, increased full phone control adoption to more than 60% of US users and continued building the foundation for our next-generation systems.
在具韌性的經常性收入、獲利的商業模式與強健財務狀況支持下所投入的投資,推動我們在2025年策略各面向取得顯著進展。今年我們透過在九個新國家上市擴大全球規模,推出G7 CGM整合,將全手機控制的採用率提升至美國使用者的60%以上,並持續打造下一代系統的基礎。
We also advanced our clinical programs in meaningful ways. We published results from SECURE-T2D and RADIANT, completed the STRIVE study for Omnipod 6 and moved into the next phase of our EVOLUTION study supporting our fully closed loop system for adults with type 2 diabetes.
我們也以具意義的方式推進臨床計畫。我們發表SECURE-T2D與RADIANT的結果,完成Omnipod 6的STRIVE研究,並進入EVOLUTION研究的下一階段,以支持針對第二型糖尿病成人的全閉環系統。
Collectively, these programs further strengthen the scientific foundation behind Omnipod, advancing our algorithms for optimal performance, fortifying the case for broader AID adoption and enabling continued global expansion.
整體而言,這些計畫進一步強化Omnipod背後的科學基礎,推進我們的演算法以達到最佳表現,鞏固更廣泛採用AID的論證,並促成持續的全球擴張。
We invested in market development in new, more visible and impactful ways. Our expanded sales force is now more than 25% larger than our nearest competitor. Our DTC campaigns are generating record lead volumes and activating new prescribers.
我們以更新、更可見且更具影響力的方式投資市場開發。我們擴編後的銷售團隊規模如今比最近的競爭對手大25%以上。我們的DTC(直接面向消費者)行銷活動正創造創紀錄的潛在客戶量,並帶動新的開立者。
And our enhanced insights and analytics capability are helping us optimize our cost to acquire and cost to serve, driving continued expansion in customer lifetime value. These advances and efforts to solidify Omnipod's status as the most requested, most preferred and most prescribed AID system.
同時,我們強化的洞察與分析能力正協助我們最佳化獲客成本與服務成本,推動客戶終身價值持續提升。這些進展與努力旨在鞏固Omnipod作為最常被要求、最受偏好且最常被開立的AID系統之地位。
Among new customers, 70% of those who walk into a prescriber's office request a brand ask for Omnipod 5 and among existing users, Omnipod 5 maintains the highest Net Promoter Score in the category. Now I want to take a few minutes to walk through how we will continue advancing the long-term strategy we outlined at our 2025 Investor Day to extend our leadership and strengthen patient and physician choice for Omnipod.
在新客戶中,走進開立者診間的患者有70%會指名要求Omnipod 5;在既有使用者中,Omnipod 5在該類別中維持最高的淨推薦值(Net Promoter Score)。接下來我想花幾分鐘說明,我們將如何持續推進在2025年投資人日所概述的長期策略,以延伸我們的領導地位,並強化病患與醫師對Omnipod的選擇。
Innovation remains central to our strategic approach. And in 2026, we will deliver a steady cadence of highly requested enhancements to reinforce our leadership in automated insulin delivery. This includes algorithm updates that enable a 100-step point target for tighter glycemic control, increased time in automated mode and improved responsiveness to enhance both the user experience and clinical outcomes.
創新仍是我們策略方法的核心。在2026年,我們將以穩定節奏推出多項高度被期待的強化功能,以鞏固我們在自動化胰島素輸注領域的領導地位。其中包括演算法更新,使目標值可細分至100個階梯點以達到更緊密的血糖控制、增加自動模式時間,並提升反應速度,以改善使用者體驗與臨床結果。
We will also expand our CGM integrations to include FreeStyle Libre 3, making Omnipod 5 compatible with every major sensor, and we will roll out Omnipod Discover globally. Omnipod Discover is a new data platform that delivers clear, streamlined insights to support efficient healthcare professional review of Omnipod 5 data and enable more confident prescribing.
我們也將擴大CGM整合,納入FreeStyle Libre 3,使Omnipod 5與所有主要感測器相容,並將在全球推出Omnipod Discover。Omnipod Discover是一個新的資料平台,提供清晰且精簡的洞察,支援醫療專業人員更有效率地檢視Omnipod 5資料,並提升開立處方的信心。
Discover provides users with actionable guidance and reassurance, strengthening engagement and adherence. It also simplifies onboarding, reducing efforts for new users and accelerating the start-up experience. Collectively, these enhancements reduce day-to-day effort with fewer device interactions, broader CGM choice and more actionable insights that help patients and clinicians with confidence.
Discover為使用者提供可執行的指引與安心感,強化互動與遵從性。它也簡化導入流程,降低新使用者所需投入的努力並加速啟用體驗。整體而言,這些強化透過更少的裝置互動、更廣泛的CGM選擇與更可執行的洞察,降低日常負擔,協助病患與臨床人員更有信心地管理。
In 2026, we will continue to purposely increase R&D investment to advance our next-generation platforms, including Omnipod 6, as well as our fully closed-loop system for type 2 diabetes and future innovations. This also includes continued progress across our clinical programs with ongoing work in STRIVE and EVOLUTION.
在2026年,我們將持續有目的地提高研發投資,以推進下一代平台,包括Omnipod 6,以及針對第二型糖尿病的全閉環系統與未來創新。這也包括在臨床計畫上的持續進展,延續STRIVE與EVOLUTION的進行中工作。
Let me take a moment to share more on our next-generation platform, starting with Omnipod 6. This system is designed to address the critical needs of users by meaningfully reducing day-to-day burden and increasing flexibility through improved connectivity, expanded flexibility in on-body placement, real-time software updates and more personalized automation.
讓我花點時間分享更多關於我們的下一代平台,先從Omnipod 6開始。此系統旨在回應使用者的關鍵需求,透過改善連線能力、擴大身體佩戴位置的彈性、即時軟體更新與更個人化的自動化,顯著降低日常負擔並提升靈活性。
It will feature a smarter algorithm to further personalize insulin delivery with pivotal data to be presented at ADA in June. Importantly, we are designing a single updatable pod platform that will be compatible across all CGM systems. These capabilities not only improve outcomes and the wear experience but also accelerate our innovation cycle as we prepare for launch in 2027.
它將搭載更智慧的演算法,以進一步個人化胰島素輸注;關鍵性數據預計於6月在ADA上發表。重要的是,我們正在設計一個可更新的單一Pod平台,將可與所有CGM系統相容。這些能力不僅改善治療結果與佩戴體驗,也在我們為2027年上市做準備之際,加速我們的創新週期。
Turning next to our fully closed-loop system for people with type 2 diabetes, which is designed to make AID accessible to virtually everyone. As the market leader in AID, it's important that we define what fully closed loop truly means for patients and providers.
接下來談到我們針對第二型糖尿病患者的全閉環系統,其設計旨在讓 AID 幾乎人人可及。作為 AID 的市場領導者,我們必須為患者與醫療照護提供者清楚界定「全閉環」對他們真正意味著什麼。
It is a system that delivers therapy effortlessly, adapting automatically without any user intervention. No dosing, no meal time actions and no required adjustments while the pod is worn. For us, fully closed loop also means redefining the provider experience, requiring no clinician defined settings to start and simple enough for a patient to initiate on their own.
這是一套可毫不費力地提供治療的系統,能在無需任何使用者介入的情況下自動調整。無需計算劑量、無需用餐時操作,且在配戴 pod 期間不需要任何必要調整。對我們而言,全閉環也意味著重新定義醫療照護提供者的使用體驗:啟用時不需要由臨床醫師設定參數,且簡單到患者可自行啟動。
Reflecting this definition, we believe our fully closed loop system will help address a significant unmet need for the 5.5 million people with type 2 diabetes who are on insulin, only about 25% of whom achieved recommended glucose targets today. We expect to initiate our pivotal EVOLUTION study this year, supporting a regulatory filing in 2027 and a commercial launch in 2028.
基於此一定義,我們相信全閉環系統將有助於滿足 550 萬名使用胰島素的第二型糖尿病患者的一項重大未被滿足需求;目前其中僅約 25% 達到建議的血糖目標。我們預期今年啟動關鍵性 EVOLUTION 研究,以支持於 2027 年進行法規申報並於 2028 年商業上市。
Finally, operational excellence remains a core focus as we work to expand margins in 2026, while continuing to fund our R&D and commercial investments. In 2025, we delivered significant margin expansion driven by scale and ongoing manufacturing productivity with our Acton and Malaysia facilities ramping ahead of plan.
最後,營運卓越仍是核心重點;我們在持續投入研發與商業投資的同時,將致力於在 2026 年擴大利潤率。2025 年,我們在規模效益與持續的製造生產力提升帶動下,實現顯著的利潤率擴張;Acton 與馬來西亞廠區的產能爬坡進度也超前計畫。
In 2026, we expect additional leverage as we invest in more capacity and further automation. And with the help of AI, we are increasingly tapping into our unique cloud-based data ecosystem to enhance customer service efficiency and satisfaction, reducing our cost to serve while strengthening retention.
2026 年,隨著我們投資更多產能並進一步自動化,我們預期將獲得額外的營運槓桿。在 AI 的協助下,我們也日益運用獨特的雲端資料生態系來提升客服效率與滿意度,在強化留存的同時降低服務成本。
Taken together, these priorities position us extremely well to execute on our long-term strategy and continued strengthening and driving choice for Omnipod among patients and providers worldwide. All of these investments, strategies and consistent execution come together in the financial growth algorithm we introduced at our 2025 Investor Day.
綜合而言,這些優先事項使我們在執行長期策略、持續強化並推動全球患者與醫療照護提供者選擇 Omnipod 方面具備極佳的有利位置。所有這些投資、策略與一貫的執行力,最終匯聚成我們在 2025 年投資人日所介紹的財務成長演算法。
Our 2026 guidance aligns fully with this growth outlook, and Flavia will walk through the details in a moment. This outlook is supported by our continued investment in innovation, science, market development, demand generation and manufacturing balanced with the discipline that has defined our execution over the past several years.
我們對 2026 年的財測與此成長展望完全一致,Flavia 稍後將說明細節。此展望由我們持續在創新、科學、市場開發、需求創造與製造方面的投資所支撐,同時也兼顧過去數年來定義我們執行力的紀律。
We remain committed to delivering market-leading financial performance, while investing in the next wave of transformative innovation. We entered 2026 with strong momentum and clear priorities that position us well and give us confidence in achieving our financial goals.
我們仍致力於提供市場領先的財務表現,同時投資於下一波具變革性的創新。我們以強勁動能進入 2026 年,並具備清晰的優先事項,使我們處於有利位置,並對達成財務目標充滿信心。
To close, 2025 was a year of tremendous growth for Insulet, financial, strategic and organizational. We expect to build upon this in 2026 as we lighten the burden of living with diabetes for hundreds of thousands of people and in doing so, drive penetration, increase our scale and create value for our shareholders.
總結而言,2025 年對 Insulet 而言是大幅成長的一年,涵蓋財務、策略與組織層面。我們預期在 2026 年延續此趨勢,為數十萬人減輕與糖尿病共處的負擔,並藉此提升滲透率、擴大規模,為股東創造價值。
We operate from a position of strength with durable competitive advantages, a large and underpenetrated market and a purpose-driven, highly motivated team committed to finding a better way. We look forward to extending our leadership in the year ahead and beyond. Thank you for your continued support and interest in Insulet.
我們立足於優勢地位,擁有持久的競爭優勢、龐大且滲透率仍低的市場,以及一支以使命驅動、動力十足、致力於尋找更好方法的團隊。我們期待在未來一年及更長遠的時間持續擴大領導地位。感謝各位持續支持並關注 Insulet。
I'll now turn the call over to Flavia to walk through the financials and guidance in more detail.
接下來我將把電話會議交給 Flavia,由她更詳細說明財務表現與財測。
Flavia Pease - Chief Financial Officer, Executive Vice President
Flavia Pease - Chief Financial Officer, Executive Vice President
Thank you, Ashley, and good morning, everyone. The Insulet team had another strong year in 2025 and closed with an impressive fourth quarter, delivering over $780 million in total revenue, an increase of 31.2% at reported rates and 29% at constant currency rates.
謝謝你,Ashley,各位早安。Insulet 團隊在 2025 年再度交出強勁的一年,並以亮眼的第四季作結,總營收超過 7.8 億美元;按報告匯率計成長 31.2%,按固定匯率計成長 29%。
During the quarter, total Omnipod grew 31.3% on a constant currency basis. We generated total revenue of over $2.7 billion in 2025, an increase of 30.7% at reported rates and 29.5% at constant currency rates. For the year, total Omnipod grew 30.3% on a constant currency basis, showcasing sustained global demand for Omnipod 5.
本季 Omnipod 總體在固定匯率基礎上成長 31.3%。2025 年我們創造超過 27 億美元的總營收;按報告匯率計成長 30.7%,按固定匯率計成長 29.5%。全年 Omnipod 總體在固定匯率基礎上成長 30.3%,展現 Omnipod 5 持續的全球需求。
Across both fourth quarter and full year, we achieved record new customer starts in the US, international markets and company-wide, with growth accelerating on both a year-over-year and sequential basis. In the US, during the fourth quarter, over 85% of new customer starts came from MDI and type 2 represented over 40% of all starts, underscoring the significant expansion of this customer segment.
無論第四季或全年,我們在美國、國際市場以及全公司層面皆創下新客啟用數的紀錄,且成長在年對年與季對季基礎上均加速。在美國,第四季超過 85% 的新客啟用來自 MDI,而第二型糖尿病占所有啟用的 40% 以上,凸顯此客群的顯著擴張。
Our estimated global utilization and annualized retention rate remained roughly stable for the fourth quarter and the full year. Now turning to our performance in greater detail. US Omnipod revenue grew 28% in the fourth quarter and 27.2% for the year, above the high end of our guidance range, driven by continued demand for Omnipod 5, across type 1 and type 2 customers.
我們估計的全球使用率與年化留存率在第四季與全年大致維持穩定。接下來更詳細說明我們的表現。美國 Omnipod 營收第四季成長 28%,全年成長 27.2%,高於我們財測區間上緣,主要由 Omnipod 5 在第一型與第二型客戶中的持續需求所帶動。
As we commented last quarter, US revenue growth during 2025, was impacted by rebate timing and prior year inventory stocking dynamics. Normalizing for these impacts, US growth in the fourth quarter was approximately 30 basis points higher representing an acceleration from normalized third quarter growth levels.
如同我們上季所提及,2025 年美國營收成長受到回扣(rebate)認列時點以及前一年庫存備貨動態的影響。若將這些影響因素正常化,第四季美國成長率約高出 30 個基點,代表相較於正常化後的第三季成長水準有所加速。
Our international Omnipod business grew 50.7% on a reported basis and 41.7% on a constant currency basis for the fourth quarter. For the full year, International Omnipod revenue grew 44.1% on a reported basis and 39.3% on a constant currency basis.
我們的國際 Omnipod 業務在第四季按報告基礎成長 50.7%,按固定匯率基礎成長 41.7%。全年而言,國際 Omnipod 營收按報告基礎成長 44.1%,按固定匯率基礎成長 39.3%。
Volume was the primary driver of international Omnipod growth, while positive price mix realization continue to contribute as customers shift from Omnipod DASH to Omnipod 5. As in prior quarters, we witnessed strong growth in the UK, Germany and France, in addition to the other countries where we have launched Omnipod 5.
銷量是國際 Omnipod 成長的主要驅動因素;同時,隨著客戶從 Omnipod DASH 轉換至 Omnipod 5,正向的價格組合實現也持續貢獻。與先前季度相同,我們在英國、德國與法國,以及其他已推出 Omnipod 5 的國家,均見到強勁成長。
In 2025, our nine expansion markets collectively delivered growth in line with the UK and Germany combined, reflecting the broad market appeal of Omnipod 5 and benefits to patients globally. Continuing down the P&L, our fourth quarter gross margin was 72.5%, reflecting a 40 basis point expansion year-over-year.
2025 年,我們九個擴張市場合計交出與英國及德國合計相當的成長,反映 Omnipod 5 廣泛的市場吸引力以及對全球患者的效益。沿著損益表往下看,我們第四季毛利率為 72.5%,年對年擴張 40 個基點。
Our full year 2025 gross margin of 71.6% reflected a 180 basis point expansion year-over-year. This improvement was fueled by robust top line growth, continued manufacturing productivity gains at our Acton and Malaysia facilities, supported by positive pricing and increased volumes. As mentioned last quarter, Malaysia became margin accretive just one year after coming online.
2025 年全年毛利率為 71.6%,年對年擴張 180 個基點。此改善由強勁的營收成長所帶動,並受惠於 Acton 與馬來西亞廠區持續的製造生產力提升,在正向定價與出貨量增加的支持下實現。如上季所述,馬來西亞廠在上線僅一年後即轉為增厚毛利(margin accretive)。
Turning to OpEx. We continue to make purposeful investments to both maintain and extend our leadership. We are fortunate to be in a position where we can meaningfully fund our innovation pipeline and ensure we are first to deliver truly transformational technology to the market.
接下來談營業費用(OpEx)。我們持續進行有目的的投資,以維持並擴大我們的領導地位。我們很幸運處於一個能夠大幅資助創新管線的地位,並確保我們率先將真正具變革性的技術推向市場。
In line with this commitment, we increased R&D spending by 50% in the fourth quarter and 37% for the full year, as we advanced our innovation road map and clinical development programs, including our STRIVE and EVOLUTION studies. At the same time, we remain disciplined and targeted in our SG&A investments.
為呼應此承諾,隨著我們推進創新路線圖與臨床開發計畫(包括 STRIVE 與 EVOLUTION 研究),我們第四季研發支出增加 50%,全年增加 37%。同時,我們在 SG&A 投資上仍維持紀律並聚焦重點。
We continue to prioritize market development initiatives to unlock AID penetration, and demand generation efforts, including expanding our commercial and customer experience teams to drive share and increase retention of our leading AID technology across both type 1 and type 2 diabetes.
我們持續優先推動市場開發計畫以提升 AID 滲透率,並推進需求創造工作,包括擴編商業與客戶體驗團隊,以在第一型與第二型糖尿病領域推動市占並提高我們領先 AID 技術的留存率。
For the year, we successfully optimized both our cost to acquire and our cost to serve. Two key metrics we remain focused on improving as we enhance customer lifetime value. Fourth quarter adjusted operating margin of 18.7% reflected robust revenue growth, strong gross margins and continued investment to advance innovation and key commercial strategies.
全年而言,我們成功優化了獲客成本與服務成本。這兩項是我們在提升客戶終身價值時持續聚焦改善的關鍵指標。第四季調整後營業利益率為 18.7%,反映強勁的營收成長、穩健的毛利率,以及持續投入以推進創新與關鍵商業策略。
Our full year adjusted operating margin was 17.6%, ahead of our most recent guidance and representing 270 basis points of expansion versus the prior year. As Ashley mentioned, we are well positioned to continue investing robustly for future growth while delivering meaningful margin expansion for years to come.
我們全年調整後營業利益率為17.6%,高於我們最近一次的指引,且較前一年擴張270個基點。如Ashley所提到的,我們已做好充分準備,能在持續大力投資以推動未來成長的同時,於未來多年實現具意義的利潤率擴張。
Fourth quarter net interest expense was $9.2 million, an increase of $11 million relative to prior year, primarily driven by the debt refinancing. Full year net interest expense was $24.7 million, an increase of $22 million compared to the prior year. Again, primarily driven by impact of our senior unsecured notes issued in March.
第四季淨利息費用為920萬美元,較前一年增加1,100萬美元,主要由債務再融資所致。全年淨利息費用為2,470萬美元,較前一年增加2,200萬美元。同樣地,主要是受我們於3月發行的高級無擔保票據影響。
Our fourth quarter non-GAAP adjusted tax rate was 22%, and our full year non-GAAP adjusted tax rate was 22.3%. Fourth quarter adjusted EPS was $1.55, increasing 35% from $1.15 in the prior year comparable period. While full year 2025 adjusted EPS was $4.97, up 53% from $3.24 in the prior year. During the year, we repurchased approximately 184,000 shares for $59.6 million.
我們第四季非GAAP調整後有效稅率為22%,全年非GAAP調整後有效稅率為22.3%。第四季調整後每股盈餘(EPS)為1.55美元,較前一年同期的1.15美元成長35%。全年2025年調整後EPS為4.97美元,較前一年的3.24美元成長53%。年內,我們以5,960萬美元回購約184,000股。
Turning to cash and liquidity. We ended the quarter with $760 million in cash and the full $500 million available under our credit facility. We delivered more than $375 million in free cash flow for 2025, a 24% increase over last year.
接著談現金與流動性。本季末我們持有7.60億美元現金,且我們的信貸額度中仍有完整的5.00億美元可用。我們在2025年創造超過3.75億美元的自由現金流,較去年增加24%。
2025 free cash flow included approximately a $70 million tax benefit related to the One Big Beautiful Bill. As a reminder, free cash flow includes capital expenditures which grew meaningfully in the fourth quarter to $135 million, reflecting our continued investment in manufacturing capacity.
2025年自由現金流包含約7,000萬美元、與《One Big Beautiful Bill》相關的稅務利益。提醒一下,自由現金流包含資本支出;第四季資本支出顯著增加至1.35億美元,反映我們持續投資於製造產能。
This included further expansion of our Malaysia operations, with additional lines coming online as well as the start of development of our new facility in Costa Rica, which is expected to be operational in 2029. These investments strengthen our global footprint, advance our automation initiatives and position us to support industry-leading growth while continuing to expand margins over time.
其中包括進一步擴張我們在馬來西亞的營運,新增產線陸續投產,以及啟動我們在哥斯大黎加新廠的開發,預計將於2029年投入營運。這些投資強化我們的全球布局、推進自動化計畫,並使我們得以支援業界領先的成長,同時隨時間持續擴大利潤率。
Now turning to our outlook for the first quarter and full year 2026. For the first quarter, we expect Omnipod revenue to grow 28% to 30% with total company growth of 25% to 27%. On a reported basis, foreign currency is expected to provide a favorable impact of about 200 basis points to both measures.
現在談我們對2026年第一季與全年展望。第一季方面,我們預期Omnipod營收成長28%至30%,公司整體成長25%至27%。以報告基礎(reported basis)計,預期外匯將對兩項指標皆帶來約200個基點的正面影響。
In the US, we anticipate Omnipod growth of 24% to 26% and in our international business, we expect Omnipod growth of 37% to 39%. On a reported basis, foreign currency is expected to contribute a favorable impact of roughly 1,100 basis points to international growth.
在美國,我們預期Omnipod成長24%至26%;在國際業務方面,我們預期Omnipod成長37%至39%。以報告基礎計,預期外匯將對國際成長貢獻約1,100個基點的正面影響。
Turning to our full year 2026 outlook. We expect our total Omnipod revenue to grow 21% to 23% and our total company revenue to grow 20% to 22%. We expect a favorable impact of 100 basis points from foreign currency for the year.
接著談我們2026年全年展望。我們預期Omnipod總營收成長21%至23%,公司總營收成長20%至22%。我們預期全年外匯將帶來100個基點的正面影響。
Our guidance reflects continued top-tier market-leading growth, but I know you will all ask me, why is growth decelerating? Just a couple of quick notes on this. First, this year, we will be anniversarying the first full year of the US launch of Omnipod for type 2, which was a significant contributor to last year's performance.
我們的指引反映持續的頂尖、具市場領導地位的成長,但我知道各位都會問我:為什麼成長在放緩?這裡簡單說明幾點。第一,今年我們將迎來Omnipod在美國針對第二型糖尿病(type 2)上市的第一個完整年度的周年比較,而這是去年表現的重要貢獻來源。
In addition, we're beginning to annualize several of our international launches, which continue to ramp well but create more challenging year-over-year comparisons. These year-over-year comp dynamics are reflected in our 2026 guidance.
此外,我們也開始對多個國際市場的上市進行年度化比較;這些市場持續良好爬坡,但會使年對年比較更具挑戰。這些年對年比較的動態已反映在我們的2026年指引中。
For US Omnipod, we expect our revenue to grow 20% to 22% driven by increased penetration from MDI users and competitive gains. We expect year-over-year growth in US new customer starts for the year and we assume similar trends in pricing, utilization and retention as we saw in 2025. For international Omnipod, we expect 2026 revenue to grow 24% to 26%.
就美國Omnipod而言,我們預期營收成長20%至22%,主要由MDI使用者滲透率提升與競爭性市占提升所帶動。我們預期全年美國新客戶啟用數(new customer starts)將年對年成長,並假設定價、使用量(utilization)與留存(retention)的趨勢與2025年相近。就國際Omnipod而言,我們預期2026年營收成長24%至26%。
On a reported basis, we expect a favorable impact of approximately 300 basis points from foreign currency. We expect year-over-year growth in international new customer starts for the year as we penetrate further in current markets and expand Omnipod 5 into new markets.
以報告基礎計,我們預期外匯將帶來約300個基點的正面影響。我們預期全年國際新客戶啟用數將年對年成長,因我們在既有市場進一步滲透,並將Omnipod 5擴展至新市場。
Omnipod 5 is now available in 19 countries, including 5 recent additions in the Middle East, and we will continue to broaden our reach and plan to enter Spain by late 2026. While value remains the primary driver of our international revenue growth, our guidance also reflects a benefit from positive price mix realization, as customers continue to transition from Omnipod Dash to Omnipod 5.
Omnipod 5目前已在19個國家上市,其中包含中東近期新增的5個國家;我們將持續擴大覆蓋範圍,並計畫於2026年末前進入西班牙。雖然價值(value)仍是推動我們國際營收成長的主要動能,但我們的指引亦反映正向的價格組合實現(price mix realization)所帶來的助益,因客戶持續從Omnipod Dash轉換至Omnipod 5。
Overall, our international growth guidance assumes stable utilization and slightly improving retention from 2026 relative to 2025. Turning to 2026 operating margin. In line with the annual guidance we provided at our recent Investor Day, we expect to drive approximately 100 basis points of operating margin expansion for the full year, reflecting strong top line growth, modest gross margin expansion, a significant step-up in R&D investments to fuel our innovation pipeline and leverage SG&A spend.
整體而言,我們的國際成長指引假設相較於2025年,2026年的使用量維持穩定、留存率略有改善。接著談2026年營業利益率。與我們在近期投資人日所提供的年度指引一致,我們預期全年可推動約100個基點的營業利益率擴張,反映強勁的營收成長、溫和的毛利率擴張、為推動創新管線而大幅提高的研發投資,以及SG&A費用的槓桿效益。
Looking at a few items below our operating income. We expect 2026 net interest expense to total approximately $40 million, primarily due to lower interest income, and we expect 2026 non-GAAP tax rate to be in the range of 22% to 23%. Our team is actively focused on assessing potential opportunities to optimize our interest expense and tax rate over time. Turning to shares outstanding and EPS.
再看幾項位於營業利益以下的項目。我們預期2026年淨利息費用合計約4,000萬美元,主要因利息收入降低;並預期2026年非GAAP稅率介於22%至23%。我們團隊正積極評估,隨時間推進是否有機會優化利息費用與稅率。接著談流通股數與EPS。
I'm pleased to share that the Board has approved an additional [$350 million] share repurchase authorization. We expect to deploy approximately $300 million of this authorization in the first quarter of 2026.
我很高興分享,董事會已核准額外[3.50億美元]的庫藏股回購授權。我們預期在2026年第一季動用其中約3.00億美元。
Our strong balance sheet gives us the flexibility to continue allocating capital in line with our long-standing principles, investing for growth while delivering long-term value for our shareholders. Based on our current share count and repurchase plans, we expect the 2026 ending balance of our diluted share count to be around 70 million shares. Based on these factors, we expect 2026 adjusted EPS to increase by more than 25%.
我們強健的資產負債表,讓我們能依循長期以來的資本配置原則保持彈性:在投資成長的同時,為股東創造長期價值。基於目前股數與回購計畫,我們預期2026年期末稀釋後流通股數約為7,000萬股。基於上述因素,我們預期2026年調整後EPS將成長超過25%。
We expect free cash flow to be approximately flat from 2025 levels, supported by robust growth and continued margin expansion, partially offset by a ramp-up in capital expenditures to support our continued global manufacturing expansion plan.
我們預期自由現金流將與2025年水準大致持平,受惠於強勁成長與持續的利潤率擴張,但部分將被資本支出增加所抵銷,以支援我們持續推進的全球製造擴張計畫。
As I just mentioned, 2025 free cash flow included approximately $70 million related to a tax benefit from the One Big Beautiful Bill. Our team remains steadfast in its commitment to driving top-tier growth, expanding margins and increasing profitability and free cash flow. These efforts are central to our long-term value creation strategy and enable us to reach and serve more people with diabetes around the world.
如我剛才提到的,2025年自由現金流包含約7,000萬美元,係來自《One Big Beautiful Bill》的稅務利益。我們團隊仍堅定致力於推動頂尖成長、擴大利潤率,並提升獲利能力與自由現金流。這些努力是我們長期價值創造策略的核心,並使我們能在全球觸及並服務更多糖尿病患者。
With that, operator, please open the line for questions.
接下來,接線員,請開放提問。
Operator
Operator
(Operator Instructions) Jeff Johnson, Baird.
(接線員指示) Jeff Johnson,Baird。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Thank you. Good morning, everyone, and congratulations on a strong close to the year. Ashley, I just want to start from a high level, maybe with the first question here. You're a couple of months away from your 1-year anniversary leading Insulet.
謝謝。各位早安,也恭喜今年收官表現強勁。Ashley,我想先從較高層次切入,作為第一個問題。你距離領導Insulet滿一周年大概還有幾個月。
Stock has had a great run in the first 6 months of your tenure. It's faced maybe some challenges here in the last 5 or 6 months. What do you think is the most underappreciated part of the insulin story at this point, especially from an investor perspective? Thank you.
在您任期的前 6 個月,股價表現非常亮眼。但在過去 5 到 6 個月可能也面臨了一些挑戰。就目前而言,尤其從投資人角度來看,您認為胰島素這個故事中最被低估的部分是什麼?謝謝。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Yeah, good morning, Jeff. Thanks for the question, and it's great to see Insulet continue to execute and live into our commitments that we shared in November at our Investor Day. I would highlight four key areas. Number one is our tech lead, which we'll continue to innovate off (inaudible). I'll come back to that. I would say number two is our growing commercial powers. I'll come back to that. Three is our manufacturing at scale, and four is our financial strength. So I'll start with just our tech lead.
好的,早安,Jeff。謝謝你的提問,也很高興看到 Insulet 持續落實執行,並兌現我們在 11 月投資人日所分享的承諾。我會強調四個關鍵面向。第一是我們的技術領先,我們會持續在此基礎上創新(聽不清)。我等一下會再回到這點。第二是我們日益增強的商業能力。我也會再回到這點。第三是我們具規模化的製造能力,第四是我們的財務實力。我先從技術領先談起。
As we shared, we've invested over $3 billion to get here. Omnipod 5, we're just 3.5 years into the launch into the US, 2.5 years in places like the UK and Germany, and we continue to post record NCS. This knowledge -- this experience, and this tech lead really continue to prove the leadership that's resulted in number one most prescribed and number one most requested.
如同我們分享的,為了走到今天,我們已投入超過 30 億美元。Omnipod 5 在美國上市至今僅 3.5 年,在英國、德國等地也才 2.5 年,而我們仍持續創下新客戶啟用(NCS)紀錄。這些知識——這些經驗,以及這項技術領先,持續證明我們的領導地位,使我們成為處方量第一、需求度第一的產品。
And importantly, in my opening remarks, I've really shared how, we've built this meaningful pipeline that really addresses the biggest unmet needs in the market. And you heard us touch around really two algorithm improvements starting this actually weekend we launched a limited market release with Omnipod 5 with a lower set point advanced automated mode.
而且很重要的是,在我開場致詞中也分享了,我們已建立一個具實質意義的產品管線,真正對應市場上最大的未被滿足需求。你也聽到我們提到兩項演算法改良;其實就在這個週末,我們已針對 Omnipod 5 推出有限市場版本,提供較低目標值的進階自動化模式。
It connects with Libre 3. We're going to be launching our new data platform, so that will be going out into full market release in a couple months. We will be launching our third-generation algorithm with Omnipod 6, as we mentioned in our opening remarks.
它可與 Libre 3 連接。我們也將推出新的資料平台,因此在幾個月內會進入全面市場發布。此外,如同我們在開場致詞提到的,我們將在 Omnipod 6 上推出第三代演算法。
We're going to be posting the data and the algorithm at the ADA. And this is a meaningful advancement in personal automation, as well as over the air connectivity as well as on the bod placement with a lot of variability, which is important for patients, as well as a Omnipod.
我們會在 ADA 上公布相關數據與演算法。這在個人化自動化方面是一項重要進展,同時也包含 OTA(空中下載)連線能力,以及可在機身(pod)上進行多樣化的貼附位置選擇,這對病患很重要,也同樣適用於 Omnipod。
And you're going to hear us talk about there's been a lot of noise, if you will, in the industry, which is really good things for patients around this fully closed loop. We believe that we are in a class by ourselves of how we're going.
你也會聽到我們談到,業界對於所謂「全閉環」有很多聲量與討論;這對病患而言其實是好事。我們相信,就我們的推進方式而言,我們是獨樹一格的一個級別。
Define what fully closed loop really means. I'll come back to that in inquiry, but it's a very strong pipeline, and then our commercial prowess, I think, is really underappreciated. We have the largest sales force in the industry. We're going to evolve that sales force from messaging, from selling on simplicity and ease of use and our highly differentiated technology to our strength of clinical performance. I'll come back to that.
要先界定「全閉環」到底真正代表什麼。我稍後在問答中會再回到這點;但我們的產品管線非常強,而我認為我們的商業執行力也被低估了。我們擁有業界最大的銷售團隊。我們將讓銷售團隊的訊息主軸進化:從強調簡單易用與高度差異化的技術,轉向強調我們在臨床表現上的優勢。我也會再回到這點。
And then, as Flavia was mentioning in her opening remarks, 30,000, prescribers with Omnipod, which is up 28%. Very strong brand loyalty and we continue to have unparalleled access and affordability. We manufacture at scale. It's one thing to get regulatory approval. It's different than to manufacture.
另外,如同 Flavia 在開場致詞提到的,使用 Omnipod 的開立處方醫師已達 30,000 位,年增 28%。品牌忠誠度非常強,我們也持續維持無可比擬的可近性與可負擔性。我們具備規模化製造能力。取得法規核准是一回事。能夠量產又是另一回事。
We produce tens of millions of pods with high-quality medical grade quality at consumer electronic scale, and when we say something, we execute on what we're going to say. I'm really pleased the team is building out Malaysia. We're already margin accretive in Malaysia.
我們以消費性電子產品的規模,生產數以千萬計的 pod,同時維持高品質的醫療級水準;而且我們說到做到,能把承諾落實執行。我非常高興團隊正在擴建馬來西亞產能。我們在馬來西亞已經對毛利率有正向貢獻。
In Acton, we've improved productivity and we've already started to break ground on Costa Rica. And last is just the financial wherewithal and not only are recurring revenue models, 70% gross margin, expanding operating margin, EPS above revenue, and cash flow positive. So those are perhaps underappreciated tenets of the Insulet company. Thanks for the question, Jeff.
在 Acton,我們提升了生產力,也已開始在哥斯大黎加動工。最後是財務實力:不僅有經常性收入模式、70% 毛利率、持續擴張的營業利益率、EPS 成長高於營收成長,且現金流為正。所以,這些可能就是 Insulet 這家公司較常被低估的核心支柱。謝謝你的提問,Jeff。
Operator
Operator
Robbie Marcus, JPMorgan.
JPMorgan 的 Robbie Marcus。
Robbie Marcus - Analyst
Robbie Marcus - Analyst
Great, good morning and congrats on a good quarter. I wanted to ask, I guess it's limited to one. I wanted to ask on, new patient star trends US and outside the US, and we've seen some of your competitors stumble a bit on new patient ads recently.
很好,早安,恭喜本季表現不錯。我想問一個問題,我想應該只能問一個。我想請教美國與美國以外的新病患啟用(new patient starts)趨勢;我們看到你們的一些競爭對手最近在新增病患方面有些踉蹌。
How are you thinking -- you mentioned record new patient starts. I believe that's the US and outside the US, but you could clarify that if I'm wrong. How are you thinking about finding sources of sustainability in the new patient growth.
你們怎麼看——你提到創下新病患啟用紀錄。我理解那是美國與美國以外都有,但如果我理解錯了你也可以澄清。你們如何思考新病患成長的可持續性來源?
Type 2 is clearly a home run for you in the US. How do you keep that growing and getting larger and larger and continuing to win there? And then same question outside the US you've been moving into new geographies. How do you sustain your number one share there and continue to grow that over time? Thanks.
第二型糖尿病在美國顯然是你們的一大成功。你們要如何讓它持續成長、規模越來越大,並持續在那裡勝出?另外,美國以外你們也在進入新的地理市場。你們如何維持那邊的第一市占,並隨時間持續擴大?謝謝。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Thank you, Robbie. Yeah, we did, as I mentioned before, I think in investor, we enjoy very balanced growth from the US and -- [OUS]. We did enjoy record new customer starts in the US, as well as OUS, and our role as the category leader, as we shared, we've generated about 65% of the market growth has come from Insulet, and that really is the primary source of our volume are coming from people not in the category, and those are people on multiple daily injections.
謝謝你,Robbie。是的,如我先前提到的,我想從投資人的角度來看,我們在美國與——美國以外(OUS)之間享有非常均衡的成長。我們在美國以及 OUS 都創下新客戶啟用的紀錄;而作為品類領導者,如同我們分享的,市場成長中約有 65% 來自 Insulet。這也意味著我們的主要量能來源,是來自原本不在此品類中的人群——也就是使用每日多次注射(MDI)的人。
And so we engineer our innovations to address, to bring new customers into the market. We do enjoy about 10% of our comes from switching, and we are switching from competitive AID, but our primary source is coming from MDI. And that, we can go into Type 1 where we continue to improve new customer starts and post new records in type 1, both in the US as well as OUS.
因此我們在設計創新時,會以解決痛點、把新客戶帶進市場為目標。我們大約有 10% 的業務來自轉換(switching),而且確實有從競品的 AID 轉換過來,但我們的主要來源仍是 MDI。在第一型糖尿病方面,我們也能進一步展開:我們持續提升新客戶啟用並創下新紀錄,無論在美國或 OUS 都是如此。
In the US, that's backed by strong ADA guidelines. We mentioned that 40% of people on AID therapy, there's still a lot of room when CGM has 70% penetration. There's a 30 point spread. So backed by science, making the education to really educate on our very strong clinical performance, as well as just kind of the unbelievable unparalleled access and affordability in type 1.
在美國,這有強而有力的 ADA 指引作為後盾。我們提到,目前使用 AID 治療的人約占 40%,而 CGM 的滲透率已達 70%,仍有很大成長空間。兩者之間有 30 個百分點的差距。因此在科學證據支持下,我們會加強教育,讓市場更了解我們非常強的臨床表現,以及在第一型糖尿病上幾乎無可匹敵的可近性與可負擔性。
Type 2, Robbie, you mentioned we're at the nascent stages, 5% penetration. We have a very strong value proposition. We have very strong science. You're going to hear us talk more about kind of our strategic pivot, taking advantage of the largest channel of the number one sales force in the US of migrating from really sharing our differentiated technology into proven clinical outcomes.
第二型糖尿病方面,Robbie,你提到我們仍處於非常早期的階段,目前滲透率約 5%。我們有非常強的價值主張。我們也有非常扎實的科學證據。你將會聽到我們更深入談到我們的策略轉向:善用美國最大的通路與第一大銷售團隊,從過去主要溝通差異化技術,轉為強調已被證實的臨床結果。
It's something quite frankly, we own. There's a bit of a misperception in the marketplace that we have to correct and stand and set the record straight, which is -- in addition to our, if you will, preferred form factor and preferred user experience, we have very robust clinical performance on A1C reduction and improved time and range, not just in our clinical trials, but importantly in two independent studies just recently that compared AID systems.
坦白說,這是我們的強項。市場上存在一些需要我們修正的誤解,我們必須澄清並把事實講清楚:除了我們(如果你願意這麼說)更受偏好的外型設計與使用者體驗之外,我們在 A1C 降幅與提升達標時間(time in range)方面也有非常強健的臨床表現——不僅在臨床試驗中如此,更重要的是,在最近兩項比較 AID 系統的獨立研究中也得到證實。
Omnipod's A1C was unsurpassed and our time and range was similar. So we're going to take that message and that science to the largest channel of us of our P&O, which is our field force. Thanks for the question, Robbie.
Omnipod 的 A1C 表現無可匹敵,而我們的時間範圍(Time in Range)也相近。因此,我們會把這個訊息與這些科學證據,帶到我們 P&O 最大的通路,也就是我們的前線業務團隊。謝謝你的提問,Robbie。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
David Roman - Analyst
David Roman - Analyst
Thank you. Good morning, everyone. Maybe just sort of follow-up on Robbie's question here. Can you help us reconcile a script trend to what you're seeing in reported revenue? I think this is a dynamic that caused quite a lot of noise intra quarter.
謝謝。各位早安。我想就 Robbie 的問題再追問一下。你們能否協助我們把處方量(script)趨勢,與你們所揭露的營收表現對照起來?我認為這個動態在季度內造成了相當多的雜訊。
So can you maybe size up how new patients start trends and volume growth compares to revenue? And if script data is not the right barometer, what should investors be using to track performance? And I have one financial follow-up.
所以你們能否說明一下,新病患起始(new patient starts)趨勢與量的成長,和營收之間的比較?如果處方資料不是正確的衡量指標,投資人應該用什麼來追蹤表現?另外我還有一個財務方面的追問。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Sure, let me just turn to Flavia there. Go ahead, Flavia.
當然,我先把問題交給 Flavia。Flavia,請。
Flavia Pease - Chief Financial Officer, Executive Vice President
Flavia Pease - Chief Financial Officer, Executive Vice President
Good morning, David. Thank you for the question. Yes, we know there had been a lot of questions around script data, during the fourth quarter. So I think as a reminder, and we talked a little bit about this in the JP Morgan conference, in January.
早安,David。謝謝你的提問。是的,我們知道在第四季期間,大家對處方資料有很多疑問。所以提醒一下,我們在一月的摩根大通(JP Morgan)會議上也稍微談過。
The best -- if you were going to use script data the best would be to use total pods, and that's the best reflection of the future revenue, outlook, if not if the total pod data is not available. You can use a total script. It will not capture potential changes to longer script fills, going from a 30 day to a 60 day to a 90 day, but it's also a good second-best option.
如果你要使用處方資料,最佳方式是看「總 pod 數」(total pods),那最能反映未來營收的展望;若無法取得總 pod 資料,你可以使用「總處方數」(total script)。它無法捕捉處方補充週期變長的潛在變化,例如從 30 天改為 60 天或 90 天,但作為次佳選項也不錯。
And then finally you can use MDRX, but there's a little bit of noise on MDRX, because of samples and also different channels, specialty channel is not captured there, as you use IQVA data. And then finally in the fourth quarter there's a little bit of -- I'll say seasonality, where you see higher volume going through wholesales and specialty pharma than in other cap quarters, which is not necessarily captured in script data but affects revenue. So there are a few items that folks have to take into consideration when they extrapolate from scripts into dollars of revenue.
最後你也可以使用 MDRX,但 MDRX 會有一些雜訊,原因包括樣品(samples)以及不同通路;專科通路在那裡不會被納入,而你若使用 IQVA 資料則會不同。此外,第四季還有一點——我會稱之為季節性——你會看到經由批發與專科藥局(specialty pharma)流通的量高於其他季度,但這不一定會反映在處方資料中,卻會影響營收。因此,當大家把處方數外推成營收金額時,有幾個因素需要納入考量。
David Roman - Analyst
David Roman - Analyst
Okay, and then are you willing to provide the difference between new patient start growth and overall revenue performance?
好的,那你們願意提供新病患起始成長與整體營收表現之間的差異嗎?
Flavia Pease - Chief Financial Officer, Executive Vice President
Flavia Pease - Chief Financial Officer, Executive Vice President
No, we'll continue to provide, I'll say qualitative commentary on our -- the strength of our new customer starts, and we talk about them. Ashley just mentioned the strong performance in both US and OUS and the continued growth that we see as we continue to expand, penetration of AID, but we're not going to provide specificity on new customer start growth rates.
不會。我們會持續提供——我會說是定性的——關於新客戶起始動能的評論,並且會談到它們。Ashley 剛提到美國與美國以外(OUS)的強勁表現,以及隨著我們持續擴大 AID 滲透率所看到的持續成長,但我們不會提供新客戶起始成長率的具體數字。
Operator
Operator
Larry Biegelsen, Wells Fargo.
Larry Biegelsen,富國銀行。
Lawrence Biegelsen - Analyst
Lawrence Biegelsen - Analyst
Good morning. Thanks for taking the question, and congrats on the strong finish here. Yeah, I'm going to ask, I think Jeff's question maybe a little bit differently. So Ashley, you're guiding to 21% to 23% Omnipod growth for 2026, and you gave a three-year LRP of 20% recently.
早安。謝謝讓我提問,也恭喜你們這次強勁收官。是的,我想用稍微不同的方式問 Jeff 的問題。Ashley,你們對 2026 年 Omnipod 成長的指引是 21% 到 23%,而你們最近也給了三年期 LRP(長期計畫)約 20%。
So my question is, how are you feeling about, being able to sustain the 20% growth in light of new competition and anything new you can offer on why you think investor concerns around competition are overblown, do you think it's going to be harder for new companies to scale or compete directly with Insulet in the patch pump market, or do you think their entries will have a rising tide effect? Thank you.
所以我的問題是:在新競爭者出現的情況下,你們對維持 20% 成長的信心如何?以及你們能否補充一些新的觀點,說明為何你們認為投資人對競爭的擔憂被誇大了?你們覺得新公司會更難擴張規模或在貼片式幫浦市場與 Insulet 直接競爭,還是你們認為它們的進入會帶來「水漲船高」的效應?謝謝。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Thank you, Larry, for the question and again, I'm really pleased to see the confidence in the company even increase since our Investor Day that we shared in November. As we come as a company out of stealth mode to the position of market leadership, performance trumps everything, and again, I'll go back to some elements that I think are maybe underappreciated.
謝謝你,Larry,謝謝你的提問。而且我也很高興看到,自從我們在 11 月的投資人日分享之後,市場對公司的信心又進一步提升。當我們公司從低調模式走向市場領導地位時,表現勝過一切;我再回到幾個我認為可能被低估的要點。
Getting regulatory approval is not really the definition of impact. And we have this 25 year head start with, again $3 billion of investment that's enabled us a lot of knowledge, a lot of techno-how, a lot of experience on scale, and I think in this marketplace, if you look at history, there's been a lot of attempts because it is an attractive market.
取得法規核准並不等同於真正產生影響。我們有 25 年的領先起跑,再加上約 30 億美元的投資,讓我們累積了大量知識、技術能力(techno-how)以及規模化的經驗;而在這個市場,如果你回顧歷史,因為它很有吸引力,確實有過很多嘗試。
But I will tell you there are a lot of barriers to entry, and those really come down to manufacturing at scale with high-quality. It has to go to continuing to innovate with clinical performance and really unlocking the TAM.
但我可以告訴你,進入門檻很多,而核心在於能否以高品質進行規模化製造。同時也必須持續以臨床表現推動創新,並真正解鎖 TAM(總可服務市場)。
What's going to enable us to deliver the top tier performance is by continuing to bring new users into this category, and our pipeline is specifically designed to bring new users from MDI into the category. And I think the biggest unmet need for us is to really start to improve the acumen among the clinical base, particularly in the US, of our strong clinical performance.
能讓我們交出頂尖表現的關鍵,是持續把新使用者帶進這個品類;而我們的產品管線就是專門設計來把使用 MDI(多次每日注射)的新使用者帶入這個品類。我認為我們最大的未被滿足需求,是要真正提升臨床端——特別是在美國——對我們強勁臨床表現的理解與判斷力。
So in addition to being number one prescribed and number one most requested, predominantly because of a differentiated form factor and user experience, we also want them to know and be well aware of just the strong proven clinical performance, both efficacy and safety, and unsurpassed in the category.
因此,除了是處方量第一、也是最常被點名要求的第一名——主要是因為差異化的外型規格與使用者體驗——我們也希望他們知道並充分認識到,我們在臨床表現上(有效性與安全性)有強而有力、已被證實的成果,而且在此品類中無可匹敵。
I think that will be new information for many more clinicians and then I'm going to come back to just continuing to build on our commercial. Prowess as we go, Larry, again, I think this company has been known as being really good at technology and really good at the supply chain. What's perhaps underappreciated is this evolving commercial of having the largest sales force selling on science, very strong.
我認為這對更多臨床人員來說會是新資訊;接著我想回到我們持續強化商業端能力。Larry,這家公司一直以技術很強、供應鏈很強而聞名。但可能被低估的是,我們正在演進的商業能力:擁有規模最大的銷售團隊,以科學為訴求來銷售,實力非常強。
We're bringing new prescribers into the category. We have this beloved brand that we are activating. When we activate DTC, we generate record new leads into the category. We're converting those leads into brand. Loyalty, they become new Omnipod potters, and then we continue to have unparalleled access and affordability.
我們正在把新的開立處方醫師帶進這個品類。我們有一個深受喜愛的品牌,正在被我們啟動。當我們啟動 DTC(直接面向消費者行銷)時,我們會為這個品類帶來創紀錄的新線索(leads)。我們把這些線索轉化為品牌忠誠度,他們成為新的 Omnipod 使用者,然後我們持續提供無與倫比的可近性與可負擔性。
We've been at this pharmacy for nine years and we've built remarkable relationships with the payers and the PDMs because we have very strong clinical and economic evidence, and we're going to take that strength and continue because 100% of our portfolio is in pharmacy. So while others may be at the 10% or 30%, Omnipod's been at these nine years and will continue to have unparalleled access and affordability. So thank you for the question, Larry.
我們在藥局通路已經耕耘九年,並且與付款方(payers)以及 PDM 建立了非常出色的關係,因為我們有非常強的臨床與經濟證據;我們會把這個優勢延續下去,因為我們的產品組合 100% 都在藥局通路。所以當其他人可能只有 10% 或 30% 在藥局通路時,Omnipod 已經在這裡九年,並將持續擁有無與倫比的可近性與可負擔性。所以謝謝你的提問,Larry。
Flavia Pease - Chief Financial Officer, Executive Vice President
Flavia Pease - Chief Financial Officer, Executive Vice President
Just one final add is also the financial strengths that we have. We have best in class gross margin which has built through these investments that Ashley talked about over the years. We have free cash flow positive and that strength allows us to continue investing in the business, while at the same time being able to expand margins and that investment is in innovation.
最後再補充一點:我們也具備財務面的優勢。我們擁有同業最佳的毛利率,這是多年來透過 Ashley 所提到的這些投資所建立起來的。我們的自由現金流為正,而這樣的實力讓我們能在持續投資業務的同時,也能擴張利潤率;而這些投資是投入在創新上。
It is in unlocking the market with AID penetration and is also in capacity to invest ahead of demand when you are in a disposable form factor construct. Yeah.
這也包括透過提升 AID 滲透率來解鎖市場,並且在一次性耗材(disposable)外型規格的商業模式下,能夠在需求之前提前投資產能。是的。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Yeah. Eric's sitting here, as we shared, Larry, we've got a billion dollars that we're going to invest in R&D in just the next three years, and we also are planning new next generation platforms beyond the three-year window to stay ahead.
是的。Eric 就坐在這裡;如同我們分享的,Larry,僅在接下來三年,我們就會在研發(R&D)投入 10 億美元,而且我們也在規劃三年期之外的新一代平台,以保持領先。
Operator
Operator
Michael Polark, Wolf Research.
Michael Polark,Wolf Research。
Michael Polark - Analyst
Michael Polark - Analyst
Good morning. Thank you for taking the question. I have a question on one of your center partners. So G7 is moving to 15 days from 10 day. Is this a different pod for Insulet, or is this the same pod? And if it's a different pod, can you comment on the company's readiness to provide, integration with the 15-day sensor?
早安。謝謝讓我提問。我想問一個關於你們其中一個感測器合作夥伴的問題。所以 G7 正從 10 天延長到 15 天。這對 Insulet 來說是不同的 pod,還是同一個 pod?如果是不同的 pod,你能否評論公司在供應與 15 天感測器整合方面的準備情況?
I'm just -- I'm remembering, back to 2024, it took some time for the G7 pod to become widely available and, it kind of -- I think suppress starts for a period of time before. It was widely available and so I'd like to understand the dynamics around the move from Dexcom to 15 days. Thank you.
我只是——我記得回到 2024 年,G7 pod 要到廣泛供應花了一些時間,而且它有點——我認為在廣泛供應之前的一段時間,啟用(starts)被壓抑了。所以我想了解從 Dexcom 轉到 15 天的這個變動背後的動態。謝謝。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Thank you, Mike. And here's Eric. Why don't you talk about our sensor integrations?
謝謝你,Mike。接下來是 Eric。不如你來談談我們的感測器整合?
Eric Benjamin - Executive Vice President - Innovation, Strategy and Digital Products
Eric Benjamin - Executive Vice President - Innovation, Strategy and Digital Products
Mike, thanks for the question. As a reminder, we were actually ready with the 15-day launch, day one with Dexcom. So Omnipod 5 is compatible with the 15-day G7 now, and that's a great experience for customers. Then one of the key things that we've been focused on, as Mike is accelerating sensor integration for customers.
Mike,謝謝你的問題。提醒一下,我們其實在 Dexcom 的 15 天上市時,第一天就已經準備好了。所以 Omnipod 5 現在就與 15 天的 G7 相容,對客戶來說是很棒的體驗。接著我們一直專注的一個關鍵點,是如 Mike 所說,加速為客戶進行感測器整合。
We were ready day one with the 15 day, as Ashley mentioned earlier, we began the limited market release of our Freestyle Libre plus integration, just recently, and we're excited to bring that to market in the first half of 2026.
如 Ashley 先前提到,我們在 15 天版本上市第一天就已就緒;而且就在最近,我們開始了 Freestyle Libre plus 整合的有限市場釋出(limited market release),我們很期待在 2026 年上半年把它推向市場。
And then looking ahead to Omnipod 6, recognizing the need to evolve even faster with the market, it's part of why we're designing one pod that can be updated in market for faster innovation, so that with Omnipod 6 we can always push the latest technologies directly to pods that customers have. So we're accelerating innovation and sensor integrations now. Pleased to be on market with Dexcom 15 day and assuring that we're positioned to do that going forward.
再往前看 Omnipod 6,考量到市場需要更快演進,這也是我們為何要設計一款可在市場端更新的單一 pod,以加速創新;如此一來,透過 Omnipod 6,我們可以把最新技術直接推送到客戶手上的 pods。因此我們正在加速創新與感測器整合。很高興已經支援 Dexcom 15 天版本上市,並確保我們未來也具備持續做到這點的定位。
Operator
Operator
Travis Steed, Bank of America.
Travis Steed,美國銀行(Bank of America)。
Travis Steed - Analyst
Travis Steed - Analyst
Thanks for the question. You talked about changing your guidance philosophy, so I just wanted to make sure we had understanding of how you kind of set this year's guidance versus prior years and kind of what's been kind of [baked] in into 2026 versus kind of what's left for upside and also, do you expect record new starts in Q1 as well?
謝謝讓我提問。你們談到改變指引(guidance)哲學,所以我想確認我們是否理解你們今年的指引是如何設定、相較於過去幾年有何不同;以及你們在 2026 年已經「納入」([baked] in)了哪些因素、還有哪些可能帶來上行空間。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Thanks, Travis. Flavia over to you.
謝謝,Travis。Flavia 交給你。
Flavia Pease - Chief Financial Officer, Executive Vice President
Flavia Pease - Chief Financial Officer, Executive Vice President
Yeah, hi Travis. Good morning. We continue to set guidance with a full intent to deliver. That has not changed. The guidance that we provided today reflects a balanced view of our outlook at this point. And we will experience normal seasonality in the first quarter, which has been the case, historically between fourth quarter and first quarter, but outside of that we are very confident and pleased to be able to provide an outlook of 25% to 27% for the first quarter and 20% to 22% for the full year.
好的,嗨 Travis。早安。我們一如既往設定指引時,是以完全有意圖要達成為前提。這點沒有改變。我們今天提供的指引,反映了我們在此時點對前景的均衡看法。第一季我們會出現正常的季節性波動;歷史上第四季到第一季一直都是如此。但除此之外,我們非常有信心,也很高興能提供第一季 25% 到 27%、全年 20% 到 22% 的展望。
Operator
Operator
Joanne Wuensch, Citigroup.
Joanne Wuensch,花旗集團(Citigroup)。
Joanne Wuensch - Analyst
Joanne Wuensch - Analyst
Good morning and thank you so much for taking the question. ADA is going to be here before we know it. Is there anything in particular that we should look forward to there? And I'm also trying to key in on when are we going to get a line of sight on some of the clinical steps for Omnipod 6. Thank you.
早安,也非常感謝讓我提問。ADA 很快就要到了。那裡有沒有什麼特別值得我們期待的內容?另外我也想掌握一下,我們何時能更清楚看到 Omnipod 6 的一些臨床里程碑(clinical steps)的時間點?謝謝。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Yeah, thank you, Joanne, for the question. Yes. Thank you, Joanne, for the question. So let me maybe just key up one of the things that we'll be sharing at the ADA, which is our -- from our -- data from our feasibility study, EVOLUTION, which is around what we're calling are fully closed loop, which not all fully closed loops meet the definition of our definition.
好的,謝謝你,Joanne,這個問題。是的。謝謝你,Joanne,這個問題。我先點出一項我們會在 ADA 分享的內容:我們的——來自我們——可行性研究 EVOLUTION 的數據,這與我們所稱的「完全閉環」(fully closed loop)有關;而並非所有所謂的完全閉環,都符合我們的定義。
And I think it's important, I'm going to spend a little bit of time on this quickly and then Eric will cover the others. We are designing, as the market leader with our big eyes focused on the underserved type 2 market in the United States, where we have 5% penetration, and there's 5.5 million people on insulin that we would like to be on AID therapy since the ADI guidelines recommended therapy as the standard of care.
我認為這很重要,我會很快花一點時間說明,之後 Eric 會補充其他部分。作為市場領導者,我們把重點放在美國尚未被充分服務的第二型糖尿病市場;我們目前滲透率只有 5%,而有 550 萬名使用胰島素的人,我們希望他們能使用 AID 治療,因為 ADI 指引已將該療法建議為照護標準。
We have designed our fully closed loop to address the biggest barriers for those patients with type 2 to get on to AID therapy. It starts with our algorithm, which will be including no user intervention. It requires no dosing. It has no mealtime interactions, no adjustments for the pod worn. There's two other areas that are really important to the type 2 user base who 1 is the clinicians.
我們設計的完全閉環,是為了解決第二型患者採用 AID 治療的最大障礙。首先是我們的演算法,將包含不需要使用者介入。不需要進行劑量設定(dosing)。沒有用餐時互動,也不需要針對所佩戴的 pod 進行調整。另外還有兩個領域對第二型使用者族群非常重要,其中之一是臨床醫師。
And the clinicians, this will require no defined settings at start, which is a big barrier right now to the primary care prescribing that just don't have the time to go input all of those settings. And then third, Joanne, the big unlock is patients don't have to do 2-hour training. This is something that they can initiate on their own.
對臨床醫師而言,這套系統在開始時不需要預先定義設定值,這是目前基層醫療開立處方的一大障礙,因為他們沒有時間去輸入所有那些設定。第三點,Joanne,最大的解鎖在於:病患不必接受 2 小時的訓練。這是他們可以自行啟動的東西。
So our combination of really modernizing the training so that they can do it at home on their own time, without two hours, really unlocking prescriber or adoption, not having to put in setting really important for the primary care audience, which is really who's going to be managing patients who have type 2 diabetes.
因此,我們把訓練方式大幅現代化,讓他們可以在家、在自己的時間完成,而不需要兩小時;這真的能解鎖處方端與採用端。
And then third, really a very CGM-like experience for people with type 2 diabetes. So we're going to be sharing our data from our feasibility in -- at the ADA. But in addition to that, we have some -- our third-generation algorithm on Omnipod 6 that Eric will touch on.
另外,對第二型糖尿病患者而言,這會是一種非常類似 CGM 的體驗。因此我們將在 ADA 分享我們可行性研究的數據。除此之外,我們在 Omnipod 6 上也有一些——第三代演算法,Eric 會提到。
Eric Benjamin - Executive Vice President - Innovation, Strategy and Digital Products
Eric Benjamin - Executive Vice President - Innovation, Strategy and Digital Products
Joanne, just building on Ashley's comments about what's coming at the upcoming congresses. So ATDD will be showing the evolution data, as Ashley just described on our way towards that truly transformative fully closed loop system to unlock primary care.
Joanne,延續 Ashley 對即將到來的各項大會所分享的內容。在 ATDD,我們會展示 evolution 的數據,如 Ashley 剛才所描述,這是我們邁向真正具變革性的完全閉環系統、以解鎖基層醫療的一步。
We'll also be showing some health economic data showing favorable outcomes and ER visits for the unique fully exposable experience that is Omnipods compared to tube pumps. So really excited for what's coming at ATDD.
我們也會展示一些健康經濟學數據,顯示相較於有導管的幫浦(tube pumps),Omnipod 這種獨特、完全可穿戴(fully exposable)體驗帶來更有利的結果與急診(ER)就醫情況。我們對 ATDD 即將帶來的內容感到非常興奮。
Looking ahead to ADA, that's where we'll be publishing the pivotal results from STRIVE. That's the pivotal that supports Omnipod 6, excited to be reporting that out. And in addition, Ashley mentioned this earlier, but there are more independent third-party studies comparing clinical results of on-market AID systems coming out. And in two recent of those, Omnipod has shown unsurpassed A1C. And similar time and range to those reporting time and range using an iCGM sensor.
展望 ADA,我們將在那裡發表 STRIVE 的關鍵性試驗(pivotal)結果。這項關鍵性試驗用以支持 Omnipod 6,我們很期待能對外報告結果。另外,Ashley 先前也提到,還會有更多獨立第三方研究,將市售 AID 系統的臨床結果進行比較。而在其中兩項近期研究中,Omnipod 顯示出無可匹敵的 A1C。並且在使用 iCGM 感測器所回報的範圍內時間(time in range)方面,也呈現相近表現。
And so 1 of the other things that we're paying attention to is that it's really important to interpret clinical data based on A1C. And it's hard to compare across studies that don't use an iCGM sensor for time and range. And so there's more of those studies coming out, and you'll see us talking about those too.
因此我們也關注的另一件事是:以 A1C 來解讀臨床數據非常重要。而對於未使用 iCGM 感測器來衡量範圍內時間(time in range)的研究,跨研究比較會很困難。所以接下來還會有更多這類研究發表,你們也會看到我們就這些內容進行討論。
Operator
Operator
Richard Newitter, Truist.
Richard Newitter,Truist。
Richard Newitter - Analyst
Richard Newitter - Analyst
Hi, thanks for taking the questions and congrats on the quarter. Maybe the first one, just your type 2 mix, I think you said you actually year at about 40% of the new patient starts. I guess that would seem to imply that your type 1 segment maybe saw moderating growth leveling off in the single-digit range. I guess, is that the right way to think of it going forward? And if so, what is that? Is that share? Is that just the market kind of has started to moderate and we're getting near maturity? And then I have a follow-up.
嗨,感謝讓我提問,也恭喜本季表現。也許先問第一個,關於你們第 2 型的組合,我記得你提到新病患啟用中大約有 40% 其實是來自第 2 型。我想這似乎意味著你們第 1 型的區隔可能出現成長放緩,趨於個位數區間持平。我想,往後用這種方式來理解是對的嗎?如果是的話,那是什麼因素?是市占嗎?還是市場本身開始放緩、我們接近成熟期了?我還有一個追問。
Flavia Pease - Chief Financial Officer, Executive Vice President
Flavia Pease - Chief Financial Officer, Executive Vice President
Yeah, I'll start and maybe, Eric, can add. So yes, we had very strong type 2 performance in the fourth quarter, and there was a continuation of that strength throughout the year. We had record new customer starts for both US and international, both year-over-year and sequentially.
好的,我先回答,之後 Eric 也許可以補充。所以是的,我們在第四季第 2 型表現非常強勁,而且這股強勢在全年持續延伸。無論在美國或國際市場,我們的新客戶啟用都創下紀錄,不論是年增或季增。
To your point, Richard, type 1, it grew nicely year-over-year, and it was comparable to the third quarter, which was a record quarter for us in [CS]. The level of penetration, obviously, in type 1 is higher than Type 2. And as we continue to bring AID into those markets, you will see accelerating growth in type 2 just given that it's 5% today versus type 1 at 40% penetration of AID.
如你所說,Richard,第 1 型年增表現也不錯,且與第三季相當;第三季對我們而言是[CS] 的創紀錄季度。顯然,第 1 型的滲透率水準高於第 2 型。隨著我們持續把 AID 帶入這些市場,你會看到第 2 型成長加速,因為目前第 2 型的 AID 滲透率只有 5%,而第 1 型的 AID 滲透率約為 40%。
But we continue to source a lot of our volume from MDI, as we talked about, 85% and that's really our strategy to drive that penetration in those customer segments and internationally, which is also still very underpenetrated. Eric?
但如我們所談到的,我們仍持續從 MDI 取得大量的量能來源,占比 85%,這確實是我們的策略,用以推動這些客群以及國際市場的滲透;國際市場目前仍然滲透不足。Eric?
Eric Benjamin - Executive Vice President - Innovation, Strategy and Digital Products
Eric Benjamin - Executive Vice President - Innovation, Strategy and Digital Products
Yeah, Richard, thanks for the question. I think as Flavia described, type 1 in the US is more penetrated, and the level of new customer starts in the market is high, and so it continues to be a significant driver of growth. Ashley described it well. We've got a balanced growth portfolio, and type 1 is a big part of that.
是的,Richard,謝謝你的問題。我想如 Flavia 所描述,美國第 1 型的滲透率較高,市場中新客戶啟用的水準也很高,因此它仍然是成長的重要驅動力。Ashley 已經說得很清楚。我們有一個均衡的成長組合,而第 1 型是其中很大的一部分。
Type 2, the level of new customer starts in the market has been low, and we are accelerating that as we launch Omnipod 5 with type 2 and did so over the course of 2025, which is why you saw that mix grow. You also saw our type 1 new customer starts outside the US grow significantly year-over-year, and those three levers' US type 1, US type 2, International type 1 are going to contribute a balanced, contribution to our growth over time.
第 2 型方面,市場中新客戶啟用的水準一直偏低,而我們正透過推出適用第 2 型的 Omnipod 5 來加速這一點,並在 2025 年期間逐步推進,因此你才會看到那個組合占比上升。你也看到我們在美國以外的第 1 型新客戶啟用年增顯著;這三個槓桿——美國第 1 型、美國第 2 型、國際第 1 型——將隨時間推移,對我們的成長做出均衡的貢獻。
Richard Newitter - Analyst
Richard Newitter - Analyst
Okay, that's helpful, thanks. And maybe can you following up to Travis's question, can you put some assumption bars or around the upper and lower ends of your range or maybe in another way, what would have to happen with the to the biggest needle mover in your assumption set to be at the upper end or above?
好的,這很有幫助,謝謝。另外,延續 Travis 的問題,你能否在你們區間指引的上緣與下緣周圍加上一些假設範圍,或換個方式說,在你們假設集合中,最大的關鍵變數需要發生什麼情況,才會落在區間上緣或甚至高於上緣?
Flavia Pease - Chief Financial Officer, Executive Vice President
Flavia Pease - Chief Financial Officer, Executive Vice President
Well, we provided a guidance range, so to me that is the upper and lower end of the bars that you're describing Richard, and I think we obviously as I said earlier, we continue to set guidance with the full intent of delivering and this is our best outlook at this point given where we are in the year. Obviously, is it if we can advance AID penetration even further and faster, that will translate into us being closer to the top end of the range.
我們已提供一個指引區間,所以對我而言,那就是你所描述的上下界。並且我想,正如我先前所說,我們在設定指引時的完整意圖就是要達成;以目前年度進展來看,這是我們此刻最好的展望。顯然,如果我們能把 AID 的滲透推進得更深、更快,那就會讓我們更接近區間上緣。
Operator
Operator
Danielle Antalffy, UBS.
Danielle Antalffy,UBS。
Danielle Antalffy - Analyst
Danielle Antalffy - Analyst
Good morning, everyone. Congrats on a strong end to the year, ladies plus Eric. So my question is on the competitive [moat]. Ashley, you touched on this earlier. I do think it's underappreciated. I specifically wanted to see if you could talk a little bit about the sampling at the physician's office and sort of if you could walk through how this works, like who trains the patient to ensure they get the optimal experience and I appreciate it's still early, but what are you seeing for capture rates with that program? Thanks so much.
各位早安。恭喜年底表現強勁,各位女士加上 Eric。我的問題是關於競爭[護城河]。Ashley,你先前有提到。我確實認為市場對此低估了。我特別想請你談談在醫師診所端的試用(sampling),以及能否帶我們走一遍這是如何運作的,例如由誰來訓練病患以確保他們獲得最佳體驗;我知道仍在早期,但你們在該計畫的轉換/捕獲率方面看到了什麼?非常感謝。
Ashley Mcevoy - President, Chief Executive Officer, Director
Ashley Mcevoy - President, Chief Executive Officer, Director
Thank you, Danielle, for the question. And I guess just for context, again, I think the company is best known for just having really differentiated technology and investing ahead of the curve in supply chain and maybe pioneering this pharmacy pay-as-you-go model.
謝謝你,Danielle,謝謝你的問題。我想先補充一些背景:公司最為人所知的,仍是我們具高度差異化的技術,以及在供應鏈上超前投入,並且可能也是藥局端按用量付費(pay-as-you-go)模式的先行者。
And what I would like to see at the end of this year is a better appreciation of the commercial prowess that we've been building over the past couple of years. So we have been expanding our sales force. We expanded it around 25% last year.
而我希望在今年年底能看到的是,市場更能認可我們過去幾年所建立的商業化能力。因此我們一直在擴大銷售團隊。去年我們將其擴編約 25%。
We're continuing to do that. We call on over 17,000, so full coverage of the endos, really 10,000 of the highest prescribers. And what we're evolving is our messaging, as I mentioned earlier, in addition to selling what they've come to love, which is really this differentiated technology platform that's simple and easy to use.
我們會持續這麼做。我們覆蓋超過 17,000 位(醫師),也就是對內分泌科醫師(endos)做到完整覆蓋,尤其是約 10,000 位最高處方量的醫師。而我們正在演進的是我們的訊息傳遞:如我先前提到的,除了銷售他們已經喜愛的——也就是這個簡單、易用且具差異化的技術平台——之外。
It's why it's the gateway to the category to new users. It's easy for them to explain is also coming to educate on our really strong clinical performance. And we will continue that messaging in 2026. To make it easy to get people on pod, we're really the only AID offering that can get people on a sample. So right in the practice, they can go put a pod.
這也是為什麼它是新使用者進入該品類的入口。它也很容易讓他們解釋;同時我們也開始教育市場我們非常強勁的臨床表現。我們在 2026 年也會持續這樣的訊息傳遞。為了讓大家更容易開始使用 pod,我們幾乎是唯一能讓人先拿到樣品試用的 AID 方案。所以就在診所裡,他們就可以直接戴上一個 pod。
It's a very capital-efficient way for us to initiate trial. We've gotten a lot of really good feedback both from young children as well as grandparents, around once it's kind of that moment of delight. Once they try it on, they get the [wow] factor and we have very strong conversion ratios. In addition to the called-on universe, we also have the Starling brand is what I say, that I think is a bit underappreciated where we activate directly to consumer, make them aware of the category, make them aware of Omnipod 5 and people go in and ask the doctor for that.
對我們而言,這是一種資本效率很高的方式來啟動試用。我們從年幼孩童到祖父母族群都收到很多很好的回饋:一旦到了那個「驚喜時刻」,一旦他們試戴,就會有 [哇] 的感受,而我們的轉換比率非常強。除了我們所覆蓋的醫師群之外,我們也有我所說的 Starling 品牌——我認為這也有點被低估——我們會直接面向消費者啟動行銷,讓他們認識這個品類、認識 Omnipod 5,然後人們會去找醫師並要求使用它。
And they specifically ask for Omnipod, and that's a new category user. And we -- those then become new patients, but they also become new prescribers. And that's why you heard us talk about when we ended the year, we had 30,000 prescribers writing for Omnipod, which is up 28%.
而且他們會特別指名要 Omnipod,而這就是一位新的品類使用者。而我們——這些人接著會成為新病患,但也會成為新的開方醫師。這也是為什麼你們聽到我們提到:在年底時,為 Omnipod 開方的醫師達到 30,000 位,成長 28%。
And we're going to continue that flywheel of really creating the market and creating demand for Omnipod. Thank you for the question, Danielle.
而我們將持續推動這個飛輪,真正去創造市場並為 Omnipod 創造需求。謝謝你的問題,Danielle。
Operator
Operator
And this concludes our question-and-answer session and today's conference call. We thank you for your participation, and you may now disconnect.
以上為我們的問答環節與今天的電話會議。感謝各位的參與,現在可以掛線。